Business Context and Reporting Period
Oramed Pharmaceuticals Inc. filed this Form 8-K on June 4, 2015, to report the entry into a material definitive agreement. The company, incorporated in Delaware with principal offices in Jerusalem, Israel, engaged H.C. Wainwright & Co., LLC as its exclusive agent for a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 714,286 shares of common stock at $7.50 per share to six investors.
- Overallotment Right: Investors may purchase additional shares up to the number of initial shares at $10.00 per share, exercisable between 6 and 18 months after the initial closing.
- Expected Net Proceeds: Approximately $4,900,000 after deducting fees and expenses.
- Underwriter Compensation: H.C. Wainwright will receive a 7% fee, a 1% expense allowance, and warrants to purchase 4% of the offering shares at $10.00 per share (3-year term).
- Expected Closing Date: On or about June 10, 2015.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes
This filing represents a material change in the company's capital structure and liquidity position pending the closing of the offering. The company has secured a commitment from six investors to purchase equity, subject to customary closing conditions.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The company cautions that the expected closing date of June 10, 2015, is not guaranteed and is subject to satisfaction of customary conditions.
- Contingencies: If closing conditions are not met, the offering may not proceed.
- Legal Disclaimer: The representations and warranties in the purchase agreement are solely for the benefit of the parties involved and should not be relied upon by the public for factual information about the company's current state.
Investor Verification Checklist
- Verify the actual closing of the offering and the final amount of net proceeds received.
- Confirm the issuance of the prospectus supplement and the takedown from the Form S-3 shelf registration (File No. 333-193557).
- Monitor whether the overallotment rights are exercised by the investors within the specified 6 to 18-month window.
- Review subsequent filings for updates on the company's cash position and operational use of the raised capital.